We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)–induced neurotoxicity in control wild-type (controlwt) mice, metallothionein double knockout (MTdko) mice, metallothionein-transgenic (MTtrans) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO - induced neurodegeneratlon in Parkinson disease (PD). SIN-1–induced lipid peroxidation, reactive oxygen species synthesis, caspase-3 activation, and apoptosis were attenuated by metallothionein gene overexpression and augmented by metallothionein gene down-regulation. A progressive nigrostriatal dopaminergic neurodegeneration in weaver mutant (wv/wv) mice was associated with enhanced nitrite ion synthesis, metallothionein down-regulation, and significantly reduced dopamine synthesis and 18F-DOPA uptake as determined by high-resolution micropositron emission tomography neuroimaging. The striatal 18F-DOPA uptake was significantly higher in MTtrans mice than in MTdko and α-synuclein knockout (α-Synko) mice. These observations provide further evidence that nitric oxide synthase activation and ONOO- synthesis may be involved in the etiopathogenesls of PD, and that metallothionein gene induction may provide neuroprotection.
GhafourifarP, ColtonC.Mitochondria and nitric oxide. Antiox Redox Signal5:249–250, 2003.
5.
DehmerT, LindenauJ, HaidS, DichgansJ, SchulzJB.Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem74:2213–2216, 2001.
6.
SharmaSK, SangchotP, EbadiM.Metallothionein gene manipulation influences striatal mitochondrial ubiquinones and MPTP-induced neurotoxicity in dopaminergic neurons. XIV World Congress of Pharmacology, July 7–12, 2002, San Francisco. 14:106–107, 2002.
7.
SharmaSK, ShavaliS, El RafaeyH, EbadiM.Inhibition of α-synuclein nitration and perinuclear aggregation by antioxidants in metallothionein transgenic and aging RhO (mgko) dopaminergic neurons (abstract). FASEB J 16:686.11, 2002.
8.
SharmaS, KheradpezhouM, ShavaliS, El RefaeyH, EkenJ, HagenC, EbadiM.Neuroprotective actions of coenzyme Q10 in Parkinson's disease. Methods Enzymol382:488–509, 2004.
EbadiM, SharmaS, MuralikrishnanD, ShavaliS, JoshE, SangchotP, ChetsawangB, BrekkeL.Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease. Proc West Pharmacol Soc45:1–3, 2002.
11.
EbadiM, Brown-BorgH, El RefaeyH, SinghB, GarrettS, ShavaliS, SharmaSK.Metallothionein-mediated neuroprotection in genetically engineered mice models of Parkinson's disease. Mol Brain Res134:67–75, 2005.
12.
EbadiM, SharmaSK, GhafourifarP, Brown-BorgH, El RefaeyH.Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins. Methods Enzymol396:276–298, 2005.
EbadiM, SharmaS.Peroxynitrite and mitochondria] dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal5:319–335, 2003.
16.
SangchotP, SharmaS, ChetsawangB, PorterJ, GovitrapongP, EbadiM.Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and α-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci24:143–153, 2002.
17.
EbadiM, SharmaSK, WanpenS, AmornpanA.Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. J Cell Mol Med8:213–222, 2004.
18.
SharmaSK, EbadiM.Distribution kinetics of 18F-DOPA in Weaver mutant mice. Mol Brain Res139:23–30, 2005.
19.
CaiL, KleinJB, KangYJ.MT inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem275:38957–38960, 2001.
20.
HalaszA, PainM, TabiT, MagyarK, SzokoE.Altered nitric oxide production in mouse brain after administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or met-amphetamine. Neurochem Int44:641–646, 2004.
21.
ShiragaH, PfeifferR, EbadiM.The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. Neurochem Int23:561–566, 1993.
22.
WanpenS, GovitrapongP, ShavaliS, SangchotP, EbadiM.Salsolinol, a dopamine-derived tetrahydroisoquinoline, induces cell death by causing oxidative stress in dopaminergic SH-S-Y5Y cells, and the said effect is attenuated by metallothionein. Brain Res1005:67–76, 2004.
23.
EbadiM, IversenP, HaoR, CerutisD, RojasP, HappeH, MurrinC, PfeifferR.Expression and regulation of brain metallothionein. Neurochem Int27:1–22, 1995.
24.
MaretW.Oxidative metal release from metallothionein via zinc-thiol/disulphide interchange. Proc Natl Acad Sci U S A91:237–241, 1994.
25.
MaretW.Metallothionein/disulphide interactions, oxidative stress, and the mobilization of cellular zinc. Neurochem Int27:111–117, 1995.
26.
EbadiM, HiramatsuM, BurkeWJ, FolksDG, el-SayedMA. Metallothionein isoforms provide neuroprotection against 6-hydroxy-dopamine-generated hydroxyl radicals and superoxide anions. Proc West Pharmacol Soc41:155–158, 1998.
27.
EbadiM.Glutathione and metallothionein in neurodegeneration-neuroprotection of Parkinson's disease. Neuroendocrinol Lett18:111–122, 1998.
28.
SharmaS, EbadiM.An improved method for analyzing coenzyme Q homologues and multiple detection of rare biological samples. J Neurosci Methods137:1–9, 2004.
29.
RojasP, CerutisDR, HappeHK, MurrinJC, HaoR, PfeifferRF, EbadiM.6-Hydroxy-dopamine-mediated induction of rat brain MT-I mRNA. Neurotoxicology17:323–334, 1996.
30.
RojasP, HidalgoJ, EbadiM, RiosC.Changes of MT-I+II proteins in the brain after 1-methyl-4-phenylpyridinium administration in mice. Prog Neuropsychopharmacol Biol Psychiatry24:143–154, 2001.
BeckmanJS, KoppenolWH.Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol271:C1424–C1437, 1996.
33.
BrownRH.Amyotrophic lateral sclerosis. Recent insight from genetics and transgenic mice. Cell80:687–692, 1995.
34.
BeckmanJS.Peroxynitrite verses hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann N Y Acad Sci738:69–75, 1994.
35.
RadiR, RodriguezM, CastroL, TelleriR.Inhibition of mitochondrial transport by peroxynitrite. Arch Biochem Biophys308:89–95, 1994.
36.
SharmaSK, CarlsonE, EbadiM.Neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytology32:329–343, 2003.
37.
EbadiM, SharmaS, ShavaliS, El RefaeyH.Neuroprotective actions of selegiline. J Neurosci Res67:285–289, 2002.
LeeHS, ParkCW, KimYS.MPP+ increases the vulnerability to oxidative stress rather than directly mediating oxidative damage in human neuroblastoma cells. Exp Neurol165:164–171, 2002.
40.
EbadiM, LeuschenMP.el RefaeyH, HamadaFM, RojasP. The antioxidant properties of zinc and metallothionein. Neurochem Int29:159–166, 1996.
41.
KhataiL, GoesslerW, LorencovaH, ZanggerK.Modulation of nitric oxide mediated metal release from metallothionein by the redox state of glutathione in vitro. Eur J Biochem271:2408–2416, 2004.
